Explorer EV: Ford New Electric Vehicle in European Market

“The new line of Ford not only includes the Explorer name and some design attributes but also shares the SUV in the US which is powered by gas or a plug-in hybrid version that is right now available in Europe. The naming is a strategic step for the company to leverage its “most iconic” EV brands such as F-150 Lightning and Mustang Mach-E crossover.”

Ford Motor, the Michigan-based multinational automobile manufacturer on Tuesday disclosed its first all-new electric vehicle (EV) for the European market and said the company looks forward to leveraging the popular Explorer nameplate to gain traction.

Also Read, Oceanic+ app by Apple for Scuba Divers is here

The EV crossover is part of the automobile company to transform its European vehicle lineup to be entirely electric by 2030.

The new line of Ford not only includes the Explorer name and some design attributes but also shares the SUV in the US which is powered by gas or a plug-in hybrid version that is right now available in Europe.

The naming is a strategic step for the company to leverage its “most iconic” EV brands such as F-150 Lightning and Mustang Mach-E crossover.

Ford revealed that it is not going to provide the midsize electric crossover in the market of the US. It is one of the two vehicles expectes for the European market that leverages the Volkswagen Group’s all-electric “MEB” platform at the German factory of Ford.

Ford and Volkswagen first announced their partnership on autonomous and electric vehicles in 2019. The partnership on EVs was focused to accelerate the procedure of getting vehicles to market as Ford works on its own dedicated platform.

Ford plans to deliver 1.2 million EVs using Volkswagen’s platform in the next six years, beginning in 2023- 2X its previous production plans. Earlier plans include 600,000 EVs every year in Europe by 2026.

Covid wave looms in Europe as booster campaign makes slow start

Source: CNN

 

A new Covid-19 wave appears to be brewing in Europe as cooler weather arrives, with public health experts warning that vaccine fatigue and confusion over types of shots available will likely limit booster uptake.

Omicron subvariants BA.4/5 that dominated this summer are still behind the majority of infections, but newer Omicron subvariants are gaining ground. Hundreds of new forms of Omicron are being tracked by scientists, World Health Organization (WHO) officials said this week.

WHO data released late on Wednesday showed that cases in the European Union reached 1.5 million last week, up 8% from the prior week, despite a dramatic fall in testing. Globally, case numbers continue to decline. Hospitalization numbers across many countries in the 27-nation bloc, as well as Britain, have gone up in recent weeks.

 

New Covid Wave

 

A cargo aircraft operated by Cathay Pacific Airways Ltd. flies approaches Hong Kong International Airport in Hong Kong, China, on Tuesday, Aug. 10, 2021. Cathay is scheduled to report half-year results on Aug. 11. Photographer: Paul Yeung/Bloomberg via Getty Images

Cathay Pacific is facing ‘unprecedented staffing’ shortages, warns top union in Hong Kong

In the week ending October 4, Covid-19 hospital admissions with symptoms jumped nearly 32% in Italy, while intensive care admissions rose about 21%, compared to the week before, according to data compiled by independent scientific foundation Gimbe.

Over the same week, Covid hospitalizations in Britain saw a 45% increase versus the week earlier.

Omicron-adapted vaccines have launched in Europe as of September, with two types of shots addressing the BA.1 as well as the BA.4/5 subvariants made available alongside existing first-generation vaccines. In Britain, only the BA.1-tailored shots have been given the green light.

European and British officials have endorsed the latest boosters only for a select groups of people, including the elderly and those with compromised immune systems. Complicating matters further is the “choice” of vaccine as a booster, which will likely add to confusion, public health experts said. But willingness to get yet another shot, which could be a fourth or fifth for some, is wearing thin.

“For those who may be less concerned about their risk, the messaging that it is all over coupled with the lack of any major publicity campaign is likely to reduce uptake,” said Martin McKee, professor of European public health at the London School of Hygiene and Tropical Medicine. “So on balance I fear that uptake will be quite a bit lower.” Meanwhile, British officials last week warned that renewed circulation of flu and a resurgence in Covid-19 could pile pressure on the already stretched National Health Service.

For more updates on pharma and life science, Click here